Numerous studies have documented increases in matrix metalloproteinases (MMPs),
specifically MMP-9 levels following stroke, with such perturbations associated with …

Research on matrix metalloproteinases (MMPs) and in particular on gelatinase B, alias MMP-
9, has grown exponentially in the decade 2003–2012. Structural details about flexibility of …

Despite the enormous progress in the understanding of the course of the ischemic stroke
over the last few decades, a therapy that effectively protects neurovascular units (NVUs) and …

Traumatic brain injury (TBI) is a major cause of death in the young age group and leads to
persisting neurological impairment in many of its victims. It may result in permanent …

Stroke is one of the leading causes of mortality and morbidity, with astronomical financial
repercussions on health systems worldwide. Ischaemic stroke accounts for approximately 80 …

Ischemic stroke continues to be one of the most challenging diseases in translational
neurology. Tissue plasminogen activator (tPA) remains the only approved treatment for …

Background: Distinguishing between stroke subtypes and knowing the time of stroke onset
are critical in clinical practice. Thrombolysis and thrombectomy are very effective treatments …

Background and Purpose—Abnormal expression of some matrix metalloproteinases (MMP)
has shown to play a deleterious role in brain injury in experimental models of cerebral …

Background: Stroke is a devastating condition encompassing a wide range of
pathophysiological entities that include thrombosis, hemorrhage, and embolism. Current …

Human matrix metalloproteinases (MMPs) belong to the M10 family of the MA clan of
endopeptidases. They are ubiquitarian enzymes, structurally characterized by an active site …